Non-alcoholic Steatohepatitis Treatment Market 2026
The Non-alcoholic Steatohepatitis Treatment Market was valued at in and is anticipated to reach by , at a CAGR of 0.54 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non-alcoholic Steatohepatitis Treatment Market.
This report delivers a comprehensive overview of the Non-alcoholic Steatohepatitis Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-alcoholic Steatohepatitis Treatment Market. The Non-alcoholic Steatohepatitis Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Non-alcoholic Steatohepatitis Treatment Market Scope:
By DRUG
This report delivers a comprehensive overview of the Non-alcoholic Steatohepatitis Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-alcoholic Steatohepatitis Treatment Market. The Non-alcoholic Steatohepatitis Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non-alcoholic Steatohepatitis Treatment Market.
This report delivers a comprehensive overview of the Non-alcoholic Steatohepatitis Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-alcoholic Steatohepatitis Treatment Market. The Non-alcoholic Steatohepatitis Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Non-alcoholic Steatohepatitis Treatment Market Scope:
By DRUG
- Vitamin E
- Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib & Cenicriviroc
- Others
- Hospital pharmacy
- Retail pharmacy
- Online providers
- Allergan plc.
- Pfizer Inc
- Gilead Sciences, Inc.
- Genfit SA
- Novartis AG
- Intercepts Pharmaceuticals
- Cadila Healthcare Ltd
- Novo Nordisk
- Raptor Pharmaceutical Corp.
- Galmed Pharmaceuticals Ltd.
This report delivers a comprehensive overview of the Non-alcoholic Steatohepatitis Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-alcoholic Steatohepatitis Treatment Market. The Non-alcoholic Steatohepatitis Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. SCOPE AND METHODOLOGY
1.1. Research Methodology
1.2. Scope of the market
2. KEY TRENDS AND DEVELOPMENTS
2.1. Key Trends and Developments
3. EXECUTIVE SUMMARY
3.1. Market Snippet By Distribution Channels
3.2. Market Snippet By Drug
3.3. Market Snippet By Region
3.4. DataM CLO Scenario
4. GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) TREATMENT MARKET DYNAMICS
4.1. Market impacting factors
4.2. Drivers
4.2.1. Rise in NASH-affected population
4.2.2. Increasing prevalence of diabetes & obesity
4.2.3. Driver
4.3. Restraints
4.3.1. Insufficient diagnostic technologies for NASH
4.3.2. Restraint
4.4. Opportunity
4.5. Impact analysis
5. INDUSTRY ANALYSIS
5.1. Porter's five forces analysis
5.2. Supply chain analysis
5.3. Pricing analysis
5.4. Regulatory analysis
5.5. Pipeline analysis
6. BY DRUG
6.1. Introduction
6.2. Market size analysis, and y-o-y growth analysis (%), By Drug segment
6.3. Market attractiveness index, By Drug segment
6.4. Vitamin E
6.4.1. Introduction
6.4.2. Market size analysis, y-o-y growth analysis (%)
6.5. Pioglitazone
6.6. Ocaliva
6.7. Elafibranor
6.8. Selonsertib & Cenicriviroc
6.9. Others
7. BY DISTRIBUTION CHANNELS
7.1. Introduction
7.2. Market size analysis, and y-o-y growth analysis (%), By Distribution Channels segment
7.3. Market attractiveness index, By Distribution Channels segment
7.4. Hospital pharmacy
7.4.1. Introduction
7.4.2. Market size analysis, and y-o-y growth analysis (%)
7.5. Retail pharmacy
7.6. Online providers
8. BY REGION
8.1. Introduction
8.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
8.3. Market Attractiveness Index, By Region
8.4. North America
8.4.1. Introduction
8.4.2. Key region-specific dynamics
8.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
8.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
8.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
8.4.5.1. U.S.
8.4.5.2. Canada
8.4.5.3. Mexico
8.5. Europe
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
8.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
8.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
8.5.5.1. Germany
8.5.5.2. U.K.
8.5.5.3. France
8.5.5.4. Italy
8.5.5.5. Spain
8.5.5.6. Rest of Europe
8.6. South America
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
8.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
8.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
8.6.5.1. Brazil
8.6.5.2. Argentina
8.6.5.3. Rest of South America
8.7. Asia Pacific
8.7.1. Introduction
8.7.2. Key Region-Specific Dynamics
8.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
8.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
8.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
8.7.5.1. China
8.7.5.2. India
8.7.5.3. Japan
8.7.5.4. Australia
8.7.5.5. Rest of Asia Pacific
8.8. The Middle East And Africa
8.8.1. Introduction
8.8.2. Key Region-Specific Dynamics
8.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
8.8.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
9. COMPETITIVE LANDSCAPE
9.1. Competitive scenario
9.2. Competitor strategy analysis
9.3. Comparative type portfolio analysis
9.4. Market positioning/share analysis
9.5. Mergers and acquisitions analysis
10. COMPANY PROFILES
10.1. Allergan plc.
10.1.1. Company Overview
10.1.2. Type Portfolio And Description
10.1.3. Key Highlights
10.1.4. Financial Overview
10.2. Pfizer Inc
10.3. Gilead Sciences, Inc.
10.4. Genfit SA
10.5. Novartis AG
10.6. Intercepts Pharmaceuticals
10.7. Cadila Healthcare Ltd
10.8. Novo Nordisk
10.9. Raptor Pharmaceutical Corp.
10.10. Galmed Pharmaceuticals Ltd.
11. PREMIUM INSIGHTS
12. DATAM INTELLIGENCE
12.1. Appendix
12.2. About us and services
12.3. Contact Us
1.1. Research Methodology
1.2. Scope of the market
2. KEY TRENDS AND DEVELOPMENTS
2.1. Key Trends and Developments
3. EXECUTIVE SUMMARY
3.1. Market Snippet By Distribution Channels
3.2. Market Snippet By Drug
3.3. Market Snippet By Region
3.4. DataM CLO Scenario
4. GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) TREATMENT MARKET DYNAMICS
4.1. Market impacting factors
4.2. Drivers
4.2.1. Rise in NASH-affected population
4.2.2. Increasing prevalence of diabetes & obesity
4.2.3. Driver
4.3. Restraints
4.3.1. Insufficient diagnostic technologies for NASH
4.3.2. Restraint
4.4. Opportunity
4.5. Impact analysis
5. INDUSTRY ANALYSIS
5.1. Porter's five forces analysis
5.2. Supply chain analysis
5.3. Pricing analysis
5.4. Regulatory analysis
5.5. Pipeline analysis
6. BY DRUG
6.1. Introduction
6.2. Market size analysis, and y-o-y growth analysis (%), By Drug segment
6.3. Market attractiveness index, By Drug segment
6.4. Vitamin E
6.4.1. Introduction
6.4.2. Market size analysis, y-o-y growth analysis (%)
6.5. Pioglitazone
6.6. Ocaliva
6.7. Elafibranor
6.8. Selonsertib & Cenicriviroc
6.9. Others
7. BY DISTRIBUTION CHANNELS
7.1. Introduction
7.2. Market size analysis, and y-o-y growth analysis (%), By Distribution Channels segment
7.3. Market attractiveness index, By Distribution Channels segment
7.4. Hospital pharmacy
7.4.1. Introduction
7.4.2. Market size analysis, and y-o-y growth analysis (%)
7.5. Retail pharmacy
7.6. Online providers
8. BY REGION
8.1. Introduction
8.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
8.3. Market Attractiveness Index, By Region
8.4. North America
8.4.1. Introduction
8.4.2. Key region-specific dynamics
8.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
8.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
8.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
8.4.5.1. U.S.
8.4.5.2. Canada
8.4.5.3. Mexico
8.5. Europe
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
8.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
8.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
8.5.5.1. Germany
8.5.5.2. U.K.
8.5.5.3. France
8.5.5.4. Italy
8.5.5.5. Spain
8.5.5.6. Rest of Europe
8.6. South America
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
8.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
8.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
8.6.5.1. Brazil
8.6.5.2. Argentina
8.6.5.3. Rest of South America
8.7. Asia Pacific
8.7.1. Introduction
8.7.2. Key Region-Specific Dynamics
8.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
8.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
8.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
8.7.5.1. China
8.7.5.2. India
8.7.5.3. Japan
8.7.5.4. Australia
8.7.5.5. Rest of Asia Pacific
8.8. The Middle East And Africa
8.8.1. Introduction
8.8.2. Key Region-Specific Dynamics
8.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug
8.8.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels
9. COMPETITIVE LANDSCAPE
9.1. Competitive scenario
9.2. Competitor strategy analysis
9.3. Comparative type portfolio analysis
9.4. Market positioning/share analysis
9.5. Mergers and acquisitions analysis
10. COMPANY PROFILES
10.1. Allergan plc.
10.1.1. Company Overview
10.1.2. Type Portfolio And Description
10.1.3. Key Highlights
10.1.4. Financial Overview
10.2. Pfizer Inc
10.3. Gilead Sciences, Inc.
10.4. Genfit SA
10.5. Novartis AG
10.6. Intercepts Pharmaceuticals
10.7. Cadila Healthcare Ltd
10.8. Novo Nordisk
10.9. Raptor Pharmaceutical Corp.
10.10. Galmed Pharmaceuticals Ltd.
11. PREMIUM INSIGHTS
12. DATAM INTELLIGENCE
12.1. Appendix
12.2. About us and services
12.3. Contact Us
